



TRANSVAC2 funds a Collaboration between European and US/Canadian SMEs on a unique, single-shot SARS-CoV-2 vaccine

LiteVax BV (Oss, the Netherlands), ImmunoPrecise Antibodies (Oss, the Netherlands and Victoria, Canada) and IRTA (Barcelona, Spain) decided to combine their respective expertise in the field of immunoadjuvants, antigen design and vaccination evaluation, to develop an effective and safe SARS-CoV-2 vaccine for the globe. Feasibility of single-shot approach will be evaluated in large, nonrodent species by measuring neutralizing antibody responses and immunological memory. Based on results with similar experimental vaccines, expectations are high. The project is sponsored by TRANSVAC2, a network of leading European groups working in the field of vaccine R&D and funded by the European Commission (EC grant agreement N° 730964).

ImmunoPrecise Antibodies exploits its PolyTope™ monoclonal antibody platform for the treatment of patients against SARS-CoV-2 infection. The platform is of particular interest to identify and optimize neutralizing epitopes and to design promising antigen candidates. A selection of unique, rational-designed subunits will be investigated. LiteVax exploits a novel class of synthetic carbohydrate derivatives as vaccine adjuvant and preclinical data demonstrate that high responses and strong immunological memory are obtained already after a first vaccination. As service provider in this collaboration, IRTA (Barcelona) has all relevant expertise, know-how and facilities to conduct vaccination studies in large animal species including SARS-CoV-2 vaccines.

With the many COVID19-vaccine initiatives in advanced stage of development, opportunities for new candidates are controlled activation and modulation of the immune system; high and persistent immunity, strong memory and no immune-enhanced disease are key. Provided that results are promising, the project will be a first stepping stone towards clinical development and commercialization of the concept. Funding by TRANSVAC2/EU acts as a catalyst to crossing boundaries and building an inspiring collaboration between parties with complementary technologies. By this transatlantic collaboration we hope to contribute to the idea that global problems should be solved together.



About TRANSVAC

TRANSVAC2 is a European vaccine research and development (R&D) infrastructure that aims to accelerate the development of safe, effective and affordable vaccines that shall be one of the most successful and cost-effective public health tools for disease prevention. However, vaccine development is time-consuming and complex, requiring a combination of specialized skills and technical capacities not readily available at a single organization. In order to facilitate access to these skills and capacities, and to promote collaborations in the European vaccine landscape, TRANSVAC2 offers high quality technical services across four different service platforms: Technology (for process development and GMP production), Immunocorrelates & Systems Biology, Animal models, and support for Clinical Trials.

TRANSVAC2 has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement N° 730964.

About LiteVax

LiteVax BV is a Dutch biopharmaceutical SME with the mission to impact global health by developing and exploiting novel immunoadjuvants. Our versatile technology has the potentials to improve efficacy of a wide range of vaccines and is now evaluated in combination with various types of vaccines. For further information, please contact luuk.hilgers@litevax.com.

About ImmunoPrecise Antibodies

ImmunoPrecise is a full-service, therapeutic antibody discovery Contract Research Organization offering species agnostic, multi-format, characterized and engineered, human monoclonal antibodies, on an abbreviated timeframe, for its pharmaceutical clients. For further information, visit www.immunoprecise.com or contact solutions@immunoprecise.com.